STOCK TITAN

HCA Healthcare (HCA) SEC Filings, Sep-Nov 2026

HCA NYSE

HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.

Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.

Rhea-AI Summary

HCA Healthcare, Inc. officer Michael J. Schlosser reported a proposed sale of 1,200 common shares, with an aggregate market value of $593,583 and an approximate sale date of November 4, 2026. The shares were acquired from HCA Healthcare, Inc. on October 29, 2026, through exercise of a stock appreciation right, with compensatory payment; NYSE is listed as the sale exchange.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
other
-
Rhea-AI Summary

HCA Healthcare, Inc.'s wholly owned subsidiary HCA Inc. is offering $6.5 billion aggregate principal amount of seven senior-note series. The six fixed-rate series carry coupons of 5.200% to 6.500%; the $300 million floating-rate series pays Compounded SOFR plus 0.750%. Maturities run from November 3, 2028, through November 15, 2056.

HCA Inc. estimates net proceeds of approximately $6.430 billion after underwriting discounts and estimated offering expenses. It intends to use the proceeds for general corporate purposes, which may include redeeming all or part of the $1.200 billion outstanding 4.500% senior notes due 2027 and repaying commercial-paper or senior-credit-facility borrowings. As of September 30, 2026, HCA Healthcare's adjusted capitalization shows total debt of $50.493 billion.

HCA Healthcare guarantees the notes on a senior unsecured basis. The notes rank equally with HCA Inc.'s senior indebtedness, are structurally subordinated to subsidiary liabilities, and are effectively subordinated to secured debt to the value of its collateral. Fixed-rate notes may be redeemed under the stated terms; floating-rate notes cannot be redeemed before maturity. After a Change of Control Triggering Event, holders may require repurchase at 101% of face amount plus accrued and unpaid interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
prospectus
-
Rhea-AI Summary

HCA Healthcare, Inc.’s EVP and CFO Mike A. Marks exercised 4,585 stock appreciation rights on October 30, 2026, at $81.96 per share, receiving 4,585 common shares; 2,287 shares were delivered or withheld for payment of exercise price or tax liability. A separate October 30 holding entry lists 46,576 shares held indirectly through MAM 2020 Trust.

On November 2, 2026, Marks transferred 1,042 shares from LAM 2020 Trust to direct ownership for assets of equal value, then gifted 1,042 shares. The transfer itself did not change the shares he may be deemed to beneficially own; LAM 2020 Trust was reported with 25,458 shares following the transfer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
insider
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) EVP and Chief Clinical Officer Michael J. Schlosser exercised stock appreciation rights on October 29, 2026, acquiring 3,030 common shares at $81.96 and 1,898 shares at $82.85. Separately, 2,455 common shares were delivered or withheld for payment of exercise price or tax liability; the reported per-share price was $478.08.

Schlosser received a grant of 2,797 stock appreciation rights with an exercise price of $478.08 and an exercise date of October 29, 2027. A separate entry lists 6,951 common shares held indirectly by the 2022 Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
insider
-
Rhea-AI Summary

HCA Healthcare, Inc. announced that its wholly owned subsidiary, HCA Inc., proposes to offer senior notes, subject to market and other considerations. The notes’ principal amount, maturity and interest rate will depend on market conditions at pricing.

Separately, HCA Inc. elected to redeem all $1.200 billion of its 4.500% senior notes due February 2027 on December 2, 2026, conditioned on receiving net proceeds from the offering before the redemption date. HCA Inc. intends to use offering proceeds for general corporate purposes, which may include redeeming all or part of those notes, repaying borrowings under its $8.000 billion commercial paper program, and repaying borrowings under its senior unsecured credit facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
current report
-
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) subsidiary HCA Inc. is offering multiple series of senior notes, including fixed-rate and floating-rate notes. HCA Healthcare, Inc. will guarantee the notes on a senior unsecured basis. The notes rank equally with HCA Inc.’s senior debt, are structurally subordinated to liabilities of its subsidiaries, and effectively subordinated to secured debt to the extent of collateral value. On an as-adjusted basis after the offering and use of proceeds, the notes would be structurally subordinated to $1.005 billion of secured subsidiary debt.

HCA Inc. intends to use net proceeds for general corporate purposes, which may include redeeming all or part of its $1.200 billion of 4.500% senior notes due 2027, repaying commercial paper borrowings, or repaying borrowings under its senior unsecured credit facility. Any redemption would require a separate notice. Fixed-rate notes may be redeemed at the stated redemption prices; floating-rate notes cannot be redeemed before maturity. After a Change of Control Triggering Event, holders may require repurchase at 101% of face amount plus accrued and unpaid interest. As of September 30, 2026, HCA Healthcare, Inc. reported $50.493 billion of total debt, including $43.750 billion of senior notes and $5.727 billion of commercial paper.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
prospectus
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) reported third-quarter 2026 revenue of $19.849 billion, up 3.6% from $19.161 billion a year earlier; nine-month revenue was $59.188 billion, up 5.5% from $56.087 billion. Third-quarter net income attributable to HCA was $1.579 billion versus $1.643 billion, while diluted earnings per share were $7.27 versus $6.96.

Consolidated admissions increased 2.5%, equivalent admissions 2.8% and emergency department visits 5.3%; inpatient and outpatient surgical volumes declined 1.3% and 4.2%. Uninsured admissions increased 27.2%, and estimated third-quarter uncompensated-care cost was $1.477 billion versus $1.188 billion. HCA attributed the uninsured-admissions increase to the expiration of enhanced premium tax credits, administrative reforms and a decline in Medicaid conversions; it said those first two factors also unfavorably affected managed-care and insurer revenue.

Nine-month net cash provided by operating activities was $8.810 billion, compared with $10.277 billion. HCA repurchased 15.139 million shares at an average $430.01 per share; $4.240 billion remained available under the January 2026 authorization as of September 30, 2026. Total debt was $50.493 billion as of September 30, 2026, versus $46.492 billion as of December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
quarterly report
-
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) is named as issuer in a Rule 144 notice listing an anticipated sale by Michael S Cuffe, identified as an officer, of 11,800 common shares with an aggregate market value of $5,628,600. Merrill Lynch is listed as broker, and October 29, 2026 is the approximate sale date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
other
-
Rhea-AI Summary

HCA Healthcare, Inc. reported third-quarter 2026 revenue of $19.849 billion, up 3.6% year over year, while net income attributable to HCA declined 3.9% to $1.579 billion. Diluted EPS was $7.27, up 4.5%, and Adjusted EBITDA was $3.918 billion, up 1.2%. Operating cash flow was $4.461 billion, compared with $4.416 billion a year earlier. Same-facility equivalent admissions increased 3.0%, while same-facility inpatient and outpatient surgeries declined 1.4% and 3.7%, respectively.

HCA estimated that increased uninsured patient volume, primarily among patients who lost health-exchange coverage, had an unfavorable impact of approximately $400 million on third-quarter income before income taxes. The company now believes full-year operating results will be in the upper half of its previously issued 2026 guidance ranges, which include revenue of $77.0 billion to $79.5 billion and Adjusted EBITDA of $15.4 billion to $16.1 billion. During the quarter, HCA repurchased 7.230 million shares for $2.970 billion. Its board declared a quarterly dividend of $0.78 per share, payable December 29, 2026, to stockholders of record December 15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
current report
Rhea-AI Summary

HCA Healthcare, Inc. (HCA) reports the initial equity holdings of EVP and Chief Clinical Officer Michael J. Schlosser on a Form 3. As of September 1, 2026, he holds direct and indirect shares of common stock and a series of vested and vesting stock appreciation rights tied to HCA common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
insider

FAQ

How many HCA Healthcare (HCA) SEC filings are available on StockTitan?

StockTitan tracks 99 SEC filings for HCA Healthcare (HCA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HCA Healthcare (HCA)?

The most recent SEC filing for HCA Healthcare (HCA) was filed on November 17, 2026.